Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03383419 · ClinicalTrials.gov registry record · Phase 2
Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients
A Phase 2 study of Heart Failure, sponsored by Baylor Research Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 3
- Study locations
NCT03383419 is a Phase 2 study of Heart Failure that is actively recruiting participants, run by Baylor Research Institute. The registered enrollment target is 15 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT03383419, a Phase 2 study of Heart Failure, is actively recruiting participants, sponsored by Baylor Research Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase II, multi-center, open-label study will evaluate the safety and efficacy of utilizing HCV-positive donors for heart transplant in HCV-negative recipients treated with sofosbuvir 400 mg / velpatasvir 100 mg (Epclusa®).
Conditions Studied
Interventions
- DRUG Epclusa
Study Locations (3)
California
- Cedars-Sinai Medical Center - Los Angeles
North Carolina
- Duke University Medical Center - Durham
Texas
- Baylor University Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2018-03-20 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03383419
The ClinicalTrials.gov registry entry for NCT03383419 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower). The listed sponsor is Baylor Research Institute, which has 180 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Epclusa is the first listed.
NCT03383419 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, North Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT03383419 about?
NCT03383419 is a clinical study titled "Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients". This phase II, multi-center, open-label study will evaluate the safety and efficacy of utilizing HCV-positive donors for heart transplant in HCV-negative recipients treated with sofosbuvir 400 mg / velpatasvir 100 mg (Epclusa®).
What is the current status of trial NCT03383419?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2018-03-20. Estimated completion is 2026-12-30.
What conditions does trial NCT03383419 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT03383419?
The interventions under investigation include: Epclusa (DRUG).
Who is sponsoring clinical trial NCT03383419?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03383419 being conducted?
This trial has 3 study locations across California, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
RECRUITING · Phase 2
-
Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial
RECRUITING · Phase 2
-
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
RECRUITING · Phase 2
-
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
RECRUITING · Phase 2
-
Metformin for Pulmonary Hypertension HFpEF
RECRUITING · Phase 2
-
The Inorganic Nitrate and eXercise Performance in Heart Failure (iNIX-HF)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.